Parabilis Medicines closed a $305 million Series F to advance zolucatetide (FOG‑001) toward Phase III for desmoid tumors and to support broader development. The financing was led by RA Capital, Fidelity, and Janus Henderson, and follows an FDA Fast Track designation for FOG‑001. Parabilis said the funds will underwrite registrational studies and scale clinical operations for a candidate that inhibits β‑catenin/T‑cell factor interaction — a pathway implicated in these aggressive, non‑metastatic tumors. Investors highlighted the program’s differentiated mechanism and the opportunity to convert early clinical activity into regulatory filings.